[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patient-reported-outcome-measures\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patient-reported-outcome-measures":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,51,74,111,144,176,203,234,259,299],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100643721","evolution-of-physical-frailty-and-patient-reported-outcome-measures-in-kidney-transplant-candidates-a-mixed-methods-longitudinal-study-protocol-100643721",false,"NCT07607041","Evolution of Physical Frailty and Patient-Reported Outcome Measures in Kidney Transplant Candidates: A Mixed-Methods Longitudinal Study Protocol","Longitudinal Tracking of Physical Frailty and Health-Related Quality of Life Through Patient-Reported Outcome Measures in Adult Candidates on the Kidney Transplant Waiting List","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Diagnosed with Stage 5 chronic kidney disease (CKD).\n* Currently undergoing clinical evaluation for or actively listed on the deceased-donor kidney transplant waiting list at Hospital del Mar (Barcelona).\n* Cognitive and physical ability to understand and provide written informed consent.\n* Ability to use or have regular access to a digital device (smartphone or tablet) for electronic Patient-Reported Outcome Measures (ePROMs) completion.\n\nExclusion Criteria:\n\n* Severe cognitive impairment or active psychiatric disorders that prevent the reliable completion of questionnaires or physical tests.\n* Major physical disability that precludes the objective assessment of gait speed or handgrip strength (e.g., bilateral lower limb amputation or severe dominant hand deformity).\n* Acute medical illness requiring hospitalization at the time of enrolment.\n* Total language barrier that prevents understanding the study components or the qualitative interview.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","24 Months","OBSERVATIONAL","This study looks at how the physical and emotional health of people changes while they wait for a kidney transplant. Waiting for an organ can take a long time. During this period, some patients become \"frail.\" This means they lose strength and are at a higher risk for health problems.\n\nThe main goal is to follow these patients over time to better understand their needs. Researchers will use a mobile application to collect Patient-Reported Outcome Measures (PROMs) directly from patients about how they feel and their quality of life. The study will also include personal interviews to learn about the patients' experiences and any difficulties they face when using technology.\n\nThe results of this study will help to: • Identify early which patients are losing strength or health. • Improve the support that nurses provide during the transplant waiting period. • Make sure that digital health tools are easy for everyone to use.\n\nIn short, this work aims to help patients reach the day of their surgery in the best possible condition.",[25,26,27,28,29],"Kidney Failure, Chronic","Frailty","Quality of Life","Kidney Transplantation","Patient Reported Outcome Measures",[28,31,32,33,34,35,36,37,38],"Waiting Lists","Health-Related Quality of Life","Digital Health","Longitudinal Studies","Mixed Methods Research","Hermeneutics","Patient-Centered Care","Technology Assessment, Biomedical","NOT_YET_RECRUITING","2026-06-05",{"date":42,"type":43},"2026-06-08","ACTUAL",{"date":45,"type":20},"2026-07",{"date":47,"type":20},"2028-07",{"name":49,"class":50},"Hospital del Mar","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100643620","qor-15t-in-cardiac-surgery-100643620","NCT07593794","QoR-15T in Cardiac Surgery","Validity and Reliability of the Turkish Quality of Recovery-15 (QoR-15T) Scale in Cardiac Surgery Patients: A Prospective Observational Cohort Study","QoR15T-CARDİAC","Inclusion Criteria:\n\n* Adult patients aged 18 years and older.\n* Patients scheduled for elective cardiac surgery (CABG, valve replacement, or aortic surgery).\n* Patients capable of understanding and answering the Turkish version of the QoR-15 questionnaire.\n* Patients who provide written informed consent.\n\nExclusion Criteria:\n\n* Emergency surgeries or revision surgeries\n* Patients with severe cognitive impairment or psychiatric disorders that prevent completion of the scale\n* Patients who refuse to participate at any stage.",{"count":19,"type":20},"The objective of this prospective observational cohort study is to evaluate the validity, reliability, and responsiveness of the Turkish version of the Quality of Recovery-15 (QoR-15T) scale in adult patients undergoing elective cardiac surgery. While the QoR-15T has been validated for general surgery in Turkey, its performance remains to be established in high-risk cardiac surgery populations involving cardiopulmonary bypass and intensive care stays.Approximately 150 patients at Kocaeli City Hospital will be enrolled. The study will compare the patients' QoR-15T scores-recorded preoperatively and on the 7th postoperative day-with the Global Recovery Visual Analog Scale (VAS) to determine construct validity.",[62,29],"Postoperative Recovery","RECRUITING","2026-06-04",{"date":42,"type":43},{"date":67,"type":43},"2026-05-18",{"date":69,"type":20},"2026-10-15",{"name":71,"class":72},"Kocaeli City Hospital","OTHER_GOV",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":95,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":73},"100568638","phase-4-comparison-between-egyptian-mta-biodentine-versus-calcium-hydroxide-as-indirect-pulp-capping-materials-in-permanent-teeth-100568638","NCT06683833","Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Teeth","Comparative Analysis of Egyptian MTA, Biodentine, and Calcium Hydroxide as Indirect Pulp Capping Materials in Permanent Teeth. (A 6m Randomized Clinical Trial)","Inclusion Criteria:\n\n* Adult patients aged 22: 45 years old.\n* Males or females.\n* Patients with vital teeth with deep carious lesions.\n* Patients in good general health.\n* Good oral hygiene.\n* Co-operative patients who show interest to participate in the study.\n\nExclusion Criteria:\n\n* Patients with systemic diseases.\n* Patients with known allergic or adverse reaction to the tested materials.\n* Patients with bad oral hygiene.\n* Patient who frequently use analgesic or any drugs that could mask the pain.","22 Years","45 Years",{"count":84,"type":20},35,"INTERVENTIONAL",[87],"PHASE4","Compare the clinical performance and patient satisfaction of Egyptian MTA, Biodentine versus Calcium Hydroxide as indirect pulp capping materials in permanent teeth",[90,91,92,93,94,29],"Deep Caries","Indirect Pulp Capping","Mineral Trioxide Aggregate (MTA)","Calcium Hydroxide","Biodentine",[96,97,98,99,94,100,101],"Deep caries","Indirect pulp capping","Mineral trioxide aggregate (MTA)","Calcium hydroxide","Patient reported outcomes measures (PROMS)","Randomized clinical trial","2026-03-17",{"date":104,"type":43},"2026-03-18",{"date":106,"type":43},"2025-09-03",{"date":108,"type":20},"2026-07-03",{"name":110,"class":50},"Cairo University",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":85,"phases":121,"briefSummary":123,"conditions":124,"keywords":129,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":73},"100515395","smartphone-based-remote-symptom-monitoring-to-improve-postoperative-rehabilitation-exercise-adherence-after-video-assisted-thoracic-surgery-vats-for-lung-cancer-100515395","NCT05990946","Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer","A Prospective, Randomized, Controlled Study to Evaluate the Impact of Remote Symptom Management Via Smartphone App Based on Electronic Patient-Reported Outcomes on Rehabilitation Exercise Adherence After Minimally Invasive Surgery in Lung Cancer Patients","Inclusion Criteria:\n\n* Age 18-75 years old\n* Undergoing minimally invasive lung cancer resection\n* Able to use smartphones and complete electronic questionnaires\n* Signed informed consent\n\nExclusion Criteria:\n\n* conversions to open thoracotomy during surgery\n* ECOG score \\> 1\n* Received neoadjuvant therapy\n* Previous lung resection surgery\n* Unable to exercise due to physical limitations\n* Continuous systemic corticosteroid use within 1 month before enrollment\n* Unresolved toxicity above Grade 1 from previous treatments\n* Significant comorbidities or medical history","75 Years",{"count":120,"type":20},736,[122],"NA","Brief Summary: This randomized controlled trial aims to evaluate whether active remote symptom monitoring and management via a smartphone app utilizing electronic patient-reported outcomes (ePRO) can improve adherence to prescribed outpatient pulmonary rehabilitation exercises among postsurgical lung cancer patients. Eligible patients will use the app for perioperative care and be randomized to an intervention group receiving ePRO-based symptom monitoring with clinician feedback or a control group receiving ePRO without feedback. The primary outcome is rehabilitation exercise adherence rate over 1 month after discharge. If proven effective, the app-enabled remote rehabilitation model can be scaled up to enhance recovery for more postoperative patients.\n\nDue to slower-than-expected recruitment, an interim analysis was introduced through a protocol amendment. The amendment was approved by the Ethics Committee before conducting the analysis, and the plan was incorporated into the updated study record. The interim review evaluated feasibility and informed the addition of mean weekly exercise duration as a co-primary endpoint with adjusted statistical thresholds.",[125,126,29,127,128],"Lung Neoplasms, Non-Small Cell Lung Cancer","Postoperative Complications","Telerehabilitation","Exercise Therapy",[130,131,132,133,134],"Exercise Adherence","ePRO","Remote Monitoring","Postoperative Rehabilitation","Symptom Management","2025-11-27",{"date":137,"type":43},"2025-12-05",{"date":139,"type":43},"2023-06-01",{"date":141,"type":20},"2026-06-30",{"name":143,"class":50},"Zhongshan People's Hospital, Guangdong, China",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":152,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":85,"phases":155,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":73},"100515282","at-home-breast-oncology-care-delivered-with-e-health-solutions-100515282","NCT05989477","At-home Breast Oncology Care Delivered With E-health Solutions","At-home Breast Oncology Care Delivered With E-health Solutions The ABODE Study","ABODE","Inclusion Criteria:\n\n* Females (assigned female at birth)\\*\n* Diagnosed with first, primary invasive BC\n* Must have surgery as their first step in treatment pathway\n* Age≥18\n* Access to an electronic device with connection to the internet\n* A valid email address\n* Can communicate in English \\*Since BC risk is sex-related and based on physiological values, our inclusion criteria are based on sex (not gender)\n\nExclusion criteria:\n\n* Males (assigned male at birth), as BC surgical treatment options and experiences are different\n* Diagnosed with non-operable breast cancer\n* Stage 4\u002Fmetastatic (whether determined at diagnosis or during surgery)\n* Those with hearing or visual challenges\n* Neo-adjuvant chemotherapy\n* Should not be enrolled in any other UHN study using an e-Health application\n* Breast cancer surgery is scheduled for less 5 business days after enrollment","FEMALE",{"count":154,"type":20},200,[122],"The COVID-19 pandemic has significantly impacted healthcare service delivery, highlighting the need for high quality virtual patient care. Our team has developed a multi-dimensional remote eHealth solution for newly diagnosed breast cancer patients and their practitioners to use during the diagnostic and follow-up period. The ABODE study involved development of a Breast Cancer Treatment Application (app) which will facilitate virtual consultations, deliver patient education material, and collect patient reported outcome measures (PROMs). Using a randomized controlled trial design, the team will evaluate a variety of outcomes for breast cancer patients who will use the app throughout their diagnosis and treatment period.\n\nPrimary Objective: To compare changes in patient activation (assessed by PAM-13) over 1 year among newly diagnosed breast cancer patients between those using the app and those receiving standard care.\n\nSecondary Objectives:\n\n1. Compare additional PROMs between the standard care and intervention groups\n2. Describe health service outcomes among app users\n3. Explore end-user experience of using the app\n4. Measure activity levels using wearable devices",[158,159,29],"Patient Engagement","Patient Activation",[161,162,163,164,165,166],"e-Health","m-Health","Mobile Application","Psychosocial Oncology","Survivorship","Breast Cancer","2025-04-11",{"date":169,"type":43},"2025-04-16",{"date":171,"type":43},"2023-06-22",{"date":173,"type":20},"2026-06-22",{"name":175,"class":50},"University Health Network, Toronto",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":85,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100562467","the-effect-of-digital-education-for-osteoporosis-patients-on-fracture-risk-and-related-health-outcomes-100562467","NCT06603545","The Effect of Digital Education for Osteoporosis Patients on Fracture Risk and Related Health Outcomes.","The Effect of Digital Education for Osteoporosis Patients on Fracture Risk and Related Health Outcomes in Older Swedish Men and Women.","Inclusion Criteria:\n\n* Patients visiting an osteoporosis unit, 65 years and older.\n* Ability to understand and follow study instructions.\n* Signed informed consent.\n* Have been recommended pharmacological osteoporosis treatment after a clinical evaluation including a DXA-scan and assessment of fracture risk at an osteoporosis clinic.\n* Have access to www.1177.se.\n\nExclusion Criteria:\n\n* Patients with previous osteoporosis medication the last year.","65 Years",{"count":185,"type":20},2640,[122],"A digital education for osteoporosis patients (DEOP) has been developed and tested on patients in Region Vastra Gotaland, Sweden. Currently, the evidence regarding the efficacy of patient education on fracture risk, medication adherence, injurious falls, levels of physical activity, and diet is insufficient. Most patients with osteoporosis in Sweden are diagnosed and treated in primary care, where the knowledge about osteoporosis is often very limited. Thus, in general, osteoporosis patients are not sufficiently informed before receiving a treatment recommendation. This randomized controlled trial aims to investigate if DEOP vs. standard care can reduce the incidence of fracture in older women and men, and if the intervention leads to better adherence to osteoporosis medication, higher quality of life, increased physical activity, and enhanced diet.\n\nThe primary objective is to investigate if DEOP compared to standard care (without DEOP), can reduce the incidence of clinical fractures in men and women, over the age of 65 years, without previous osteoporosis medication the last year, who have been recommended osteoporosis treatment after a DXA scan and assessment of clinical risk factors at an osteoporosis clinic.\n\nThe secondary objectives are to investigate if DEOP compared to standard care (without DEOP), can reduce the incidence of injurious falls, have positive effects on adherence to osteoporosis medication, positively affect diet (calcium and vitamin D intake), physical activity, and improve quality of life in men and women, over the age of 65 years, without previous osteoporosis medication the last year, who have been recommended osteoporosis treatment after a DXA scan and assessment of clinical risk factors at an osteoporosis clinic.\n\nStudy design: randomized multicentre clinical trial. Patients over the age of 65 visiting an osteoporosis unit for a bone density scan (DXA) will be asked to participate in the study. The participants will be randomized to one of two arms where one arm will be invited to DEOP and the other arm will receive standard care, without DEOP.",[189,190,191,29,192,193],"Osteoporosis","Accidental Falls","Fractures, Bone","Drug Adherence","Injury Traumatic","2024-09-16",{"date":196,"type":43},"2024-09-19",{"date":198,"type":20},"2024-09",{"date":200,"type":20},"2029-12",{"name":202,"class":50},"Sahlgrenska University Hospital",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":211,"minAge":17,"maxAge":212,"enrollmentInfo":213,"targetDuration":215,"studyType":22,"phases":4,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":233},"100537548","national-robotics-assisted-radical-prostatectomy-database-100537548","NCT06279260","National Robotics-Assisted Radical Prostatectomy Database","National Robotics-Assisted Radical Prostatectomy Database: Exploring Learning Curves and Long Term Surgical, Oncological and Patient Reported Outcome Measures (PROMS)","RASOR","Inclusion Criteria:\n\nTo be eligible to participate in this database, an individual must meet all of the following criteria:\n\n1. Individuals who consent to participate,\n2. within the age range of 18 to 90 years,\n3. confirmed diagnosis of localized prostate cancer (PCa)\n4. patients receiving medical attention at hospitals engaged in collaborative efforts with the designated database.\n\nExclusion Criteria:\n\n1. Participants are not eligible to take part in the database:\n2. Individuals who have not undergone robotic surgery for prostatectomy or TP biopsy. ,\n3. without a diagnosis of prostate cancer or\n4. who decline to provide consent for the collection of their health information\n5. Under the age of 18 years.","MALE","90 Years",{"count":214,"type":20},10000,"5 Years","In Australia, nearly 70 men are diagnosed with Prostate cancer every day. Prostate removal (Radical Prostatectomy) is the proven treatment option to control cancer spread. Most of the prostate removal surgeries are done using robots. Robotic assisted prostate removal surgeries have been invented to minimise the risk of side effects post-surgery. Doctors prefer the robots over open surgery as there are benefits to patients (shorter hospital stays, lesser blood loss and better quality of life) and surgeons (better dexterity, improved field of vision and less pain). However, the cost of the robot outweighs the benefits at present and there is very less information concerning the long-term outcomes for patients.\n\nStudies conducted so far are small scale studies and the results from these studies cannot be generalized to the population at large in Australia. So, there is need for a largescale study that will look at the long-term outcomes and the factors that impact robotic surgeries across the metropolitan and rural hospital sectors.\n\nHence, this comprehensive database has been setup to collaborate with major hospitals, across metropolitan and rural areas in Australia. Through this database, researchers will be able to explore the diagnostic pathway for Prostate cancer and understand the long-term benefits of robotic surgery through patient reported questionnaires. Outcomes from this database will also help compare the quality of care against other powerhouses of robotic surgery.\n\nEventually, the database aims to standardize diagnostic pathways and clinical notes that are the same across different hospitals conducting robotic-assisted surgeries for Prostatectomy and improve care for prostate cancer patients across the country.",[218,219,220,221,222,29,223],"Database","Prostate Cancer","Robotic-assisted Radical Prostatectomy","Surgical Outcomes","Oncological Outcomes","Learning Curve","2024-08-22",{"date":226,"type":43},"2024-08-26",{"date":228,"type":43},"2024-07-01",{"date":230,"type":20},"2050-12",{"name":232,"class":50},"Melbourne Health",8,{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":85,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":258},"100550869","the-effect-of-preserving-inferior-pulmonary-ligamen-on-symptom-burden-in-thoracoscopic-pneumonectomy-100550869","NCT06452680","The Effect of Preserving Inferior Pulmonary Ligamen on Symptom Burden in Thoracoscopic Pneumonectomy","The Effect of Preserving Inferior Pulmonary Ligamen on Symptom Burden and Clinical Outcomes in Thoracoscopic Pneumonectomy","PRO-IPL","Inclusion Criteria:\n\n1. Patients underwent upper lobe resection\n2. Patients could complete our questionnaires\n\nExclusion Criteria:\n\n1. Previous history of ipsilateral lung surgery\n2. Patients who underwent pleurodesis",{"count":154,"type":20},[122],"The investigators conducted a muti-centres randomized controlled clinical trial to explore the effect of preservation of inferior pulmonary ligment compared with dissection.",[246,29],"Pulmonary Surgical Procedures",[248,246,29],"Inferior pulmonary ligment","2024-06-10",{"date":251,"type":43},"2024-06-11",{"date":253,"type":20},"2024-06",{"date":255,"type":20},"2024-08",{"name":257,"class":50},"Guangdong Provincial People's Hospital",5,{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":267,"sex":16,"minAge":17,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":85,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":73},"100462875","cancer-associated-muscle-mass---molecular-factors-and-exercise-mechanisms-100462875","NCT05307367","Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms","Identifying Molecular Factors Contributing to Cancer-associated Muscle Mass Loss and Providing Clinical Evidence for Exercise Mechanisms to Functionally Restore Muscle in Cancer","PANACEA","Inclusion Criteria, WP1+WP2X+WP2:\n\n* Men and women at or above the age of 18\n* Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb\u002FIV stage not eligible to concurrent chemo\u002Fradiation therapy as primary treatment\n* Referred for 1st line palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), this goes for WP1 + WP2\n* Referred for palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), for recurrent cancer, this goes only for WP2X.\n* Having a staging\u002Fbaseline CT within 4 weeks of initiation of treatment (PET\u002FCT are also allowed), or a baseline scan planned within the first week of treatment.\n* ECOG Performance Status 0-2\n* Having signed the informed consent form\n\nExclusion Criteria, WP1+WP2X+WP2:\n\n* Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)\n* Local palliative radiotherapy as primary treatment\n* ECOG Performance status \\> 2\n* Physical disabilities excluding physical testing\n* Inability to understand Danish\n* Inability to understand scoring systems\u002Fpatient-reported outcome measures\n\nInclusion Criteria, WP3:\n\n* Men and women above the age of 18\n* Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb\u002FIV stage\n* ECOG Performance Status 0-2\n* Having signed the informed consent form.\n\nExclusion Criteria, WP3:\n\n* Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)\n* ECOG Performance Status \\> 2\n* Physical disabilities excluding physical testing\n* Inability to understand Danish\n* Inability to understand scoring systems\u002Fpatient-reported outcome measures",true,"100 Years",{"count":270,"type":20},144,[122],"Muscle mass loss is a common adverse effect of cancer. Muscle mass loss occurs with or without reduction in body weight. Cancer cachexia (CC) is the involuntary loss of body weight of \\>5% within 6 months and it occurs in 50-80% of patients with metastatic cancer.\n\nIt is estimated that CC is a direct cause of up to 30% of all cancer-related deaths. No treatment currently is available to prevent CC, likely because the chemical reactions that causes of this devastating phenomenon in unknown.\n\nNo treatment currently is available to prevent muscle mass loss in patients with cancer but is urgently needed as the reduced muscle mass and function is associated with impaired physical function, reduced tolerance to anticancer therapy, poor quality of life (QoL), and reduced survival. There is evidence of an interdependence between informal caregiver (e.g. spouse) and patient QoL. Thus, identifying caregiver distress and needs can potentially benefit QoL for patients with cancer cachexia. Despite the enormous impact on disease outcomes, it is not known why the loss of muscle mass and function occurs and very few studies have investigated the underlying molecular causes in humans. In particular, there is a severe lack of studies that have obtained human skeletal muscle and adipose tissue sample material. Such reference sample materials will be invaluable to obtaining in-depth molecular information about the underlying molecular causes of the involuntary but common muscle mass and fat mass loss in cancer.\n\nAt a whole body level, cancer cachexia is associated with reduced sensitivity to the hormone insulin, high levels of lipids in the blood, and inflammation. Within the skeletal muscle, the muscle mass loss is associated with elevated protein breakdown and reduced protein build-up while emerging, yet, limited data also suggest malfunction of the power plants of the cells called mitochondrions. The role of malnutrition and how it contributes to weight loss is understood only to the extent of the observed loss of appetite and the reduced food intake because of pain, nausea, candidiasis of the mouth, and breathlessness. Evidence is increasing that the environment of the intestinal system could be implicated in cancer cachexia, yet, the possible effect of cancer and the cancer treatment on the intestinal environment is not understood. Thus, large and as yet poorly understood details of this syndrome precede a later weight loss.\n\nExercise training could help restore muscle function and how the chemical reactions works in cancer. In healthy people, and patients with diabetes, cardiovascular disease, and obesity exercise potently improves health. Exercise has been thought to slow down the unwanted effects of cancer cachexia by changing the reactions mentioned above. Thus, there is a tremendous gap in our knowledge of how and if exercise can restore the cells power plants function, muscle mass, strength, and hormone sensitivity in human cachexic skeletal muscle. Tackling that problem and examining potential mechanisms, will enable us to harness the benefits of exercise for optimizing the treatment of patients with cancer.\n\nThe data will provide novel clinical knowledge on cachexia in cancer and therefore addressing a fundamental societal problem.\n\nThree specific aims will be addressed in corresponding work packages (WPs):\n\n* investigate the involvement of hormone sensitivity of insulin and measure the chemical reactions between the cells in patients with lung cancer (NSCLC) and describe the physical performance and measure amount of e.g. muscles and adipose tissue across the 1st type of cancer treatment and understand how that is related to the disease and how patients and informal caregiver feel (WP1).\n* find changes in the chemical reactions in skeletal muscle, adipose tissue (AT), and blood samples in these patients, to understand how to predict how the disease will develop (WP2).\n* measure changes of skeletal muscle tissue in response to exercise and see if it might reverse the hormone insensitivity and improve muscle signaling and function (WP3).\n\nThe investigators believe that:\n\n* the majority of patients with advanced lung cancer, at the time of diagnosis already are in a cachectic state, where they lose appetite, and have hormonal changes, and an overall altered chemical actions between the cells affecting both muscle mass and AT. The investigators propose that all this can predict how the disease will progress, and how patient- and informal caregiver fell and how they rate their quality of life.\n* lung cancer and the treatment thereof is linked with changes in the blood, the muscle tissues, and the adipose tissues, especially in patients experiencing cachexia, that could be targeted to develop new treatment.\n* exercise can restore the muscles and improve insulin sensitivity and improve the function of the cells power plants in patients with lung cancer-associated muscle problems.",[274,275,276,277,278,279,280,27,281,282,283,284,29,285,286,287,288,289],"Cachexia","Neoplasms","Exercise","Metabolism","Body Composition","Insulin Resistance","Physical Functional Performance","Sarcopenia","Caregivers","Adipose Tissue","Muscle, Skeletal","Gastrointestinal Microbiome","Proteomics","Lipidomics","Epigenomics","Mitochondria","2022-05-09",{"date":292,"type":43},"2022-05-16",{"date":294,"type":43},"2022-04-01",{"date":296,"type":20},"2028-01-01",{"name":298,"class":50},"University of Copenhagen",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":267,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":73},"100358617","effects-of-exercise-therapy-and-soft-brace-on-knee-osteoarthritis-100358617","NCT03949400","Effects of Exercise Therapy and Soft Brace on Knee Osteoarthritis","Inclusion Criteria:\n\nAssigned for exercise and education due to knee osteoarthrosis Age 18 years or older at the time of recruitment Able to read and understand Danish\n\nExclusion Criteria:\n\nNot mentally able to reply to the questionnaire",{"count":306,"type":20},40,"The primary aim of the study is to investigate the effects of supervised exercise therapy and education on the immediate response to using a soft knee brace in patients with knee osteoarthritis (OA).",[309,310,311,312,313,314,29,315,316],"Rehabilitation","Treatment Outcome","Pain","Knee Brace","Outcome Assessment (Health Care)","Recovery of Function","Adults","Osteoarthritis, Knee","2019-05-10",{"date":319,"type":43},"2019-05-14",{"date":321,"type":43},"2018-04-24",{"date":323,"type":20},"2029-05-20",{"name":325,"class":50},"University College of Northern Denmark"]